{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:37:32Z","timestamp":1778276252477,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Internal resources from University of Oslo, and parties' budgets"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1000-8","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T12:53:21Z","timestamp":1534942401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score"],"prefix":"10.1186","volume":"19","author":[{"given":"Amin","family":"Ussif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege","family":"Pihlstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hallvard","family":"Holdaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut","family":"Smerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"9731","key":"1000_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381.","journal-title":"Lancet"},{"issue":"1","key":"1000_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ndt\/gfv111","volume":"31","author":"G Schlieper","year":"2016","unstructured":"Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016;31(1):31\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1000_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00774-005-0668-6","volume":"24","author":"S Jono","year":"2006","unstructured":"Jono S, Shioi A, Ikaria Y, et al. Vascular calcification in chronic kidney disease. J Bone Miner Metab. 2006;24:176\u201381.","journal-title":"J Bone Miner Metab"},{"key":"1000_CR4","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1161\/hy1001.096358","volume":"38","author":"J Blacher","year":"2001","unstructured":"Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938\u201342.","journal-title":"Hypertension"},{"key":"1000_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/j.1523-1755.2005.00303.x","volume":"67","author":"D Hernandez","year":"2005","unstructured":"Hernandez D, Rufino M, Bartolomei S, et al. Clinical impact of pre-existing vascular calcfications on mortality rate after renal transplantation. Kidney Int. 2005;67:2015\u201320.","journal-title":"Kidney Int"},{"key":"1000_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ajt.12227","volume":"13","author":"H Amer","year":"2013","unstructured":"Amer H, Griffin MD, Stegall MD, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13:1576.","journal-title":"Am J Transplant"},{"issue":"5","key":"1000_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.2013111185","volume":"26","author":"M Trillini","year":"2015","unstructured":"Trillini M, Cortinovis M, Ruggenenti P, et al. Paricacitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26(5):1205\u201314.","journal-title":"J Am Soc Nephrol"},{"key":"1000_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ckj\/sfs188","volume":"6","author":"D Hadjiyannakos","year":"2013","unstructured":"Hadjiyannakos D, Filiopoulos V, Trompouki S, et al. Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study. Clin Kidney J. 2013;6:164.","journal-title":"Clin Kidney J"},{"key":"1000_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/14656566.9.6.947","volume":"9","author":"M Cozzolino","year":"2008","unstructured":"Cozzolino M, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother. 2008;9:947.","journal-title":"Expert Opin Pharmacother"},{"key":"1000_CR10","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1111\/tri.12973","volume":"30","author":"HK Pihlstr\u00f8m","year":"2017","unstructured":"Pihlstr\u00f8m HK, Gatti F, Hammarstr\u00f6m C. Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. Transpl Int. 2017;30:2612\u201320.","journal-title":"Transpl Int"},{"key":"1000_CR11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1681\/ASN.2012030240","volume":"23","author":"A Pasch","year":"2012","unstructured":"Pasch A, Farese S, Grabver S, et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol. 2012;23:1744\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1000_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1681\/ASN.2013060635","volume":"25","author":"ER Smith","year":"2014","unstructured":"Smith ER, Ford ML, Tomlinson LA, et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol. 2014;25(2):339\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"1000_CR13","doi-asserted-by":"publisher","unstructured":".Pasch A, Block GA, Bachtler M et al. Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J Am Soc Nephrol 2017 Feb 7;12(2):315\u2013322. \n                    https:\/\/doi.org\/10.2215\/CJN.04720416\n                    \n                  . Epub 2016 Dec 9.","DOI":"10.2215\/CJN.04720416"},{"issue":"1","key":"1000_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1681\/ASN.2014070670","volume":"27","author":"CA Keyzer","year":"2016","unstructured":"Keyzer CA, de Borst MH, van den Berg E, et al. Calcification Propensity and Survival among Renal Transplant Recipients. J Am Soc Nephrol. 2016;27(1):239\u201348.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1000_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ajt.13443","volume":"16","author":"DO Dahle","year":"2016","unstructured":"Dahle DO, \u00c5sberg A, Hartmann A, et al. Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients. Am J Transplant. 2016;16(1):204\u201312.","journal-title":"Am J Transplant"},{"issue":"12","key":"1000_CR16","doi-asserted-by":"publisher","first-page":"e13131","DOI":"10.1111\/ctr.13131","volume":"31","author":"KT Smerud","year":"2017","unstructured":"Smerud KT, \u00c5sberg A, Kile HA. rapid and sustained improvement of calcification propensity score (serum T50 ) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate. Clin Transpl. 2017 Dec;31(12):e13131.","journal-title":"Clin Transpl"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1000-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1000-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1000-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T23:22:45Z","timestamp":1566429765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1000-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1000-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"23 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Regional Ethics Committee for the Oslo region (Health region south-east). All participants gave their written informed consent before any study-associated investigations were performed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AP is the inventor of the T50 test, and holds stock in Calciscon AG, Berne, Switzerland, the company that markets the T50 test. All other authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"212"}}